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Abstract: Waldenström’s macroglobulinemia (WM) is a relatively uncommon, indolent malig-
nancy of immunoglobulin M-producing B cells. The World Health Organization classifies it as a 
lymphoplasmacytic lymphoma and patients typically present with anemia, hepatosplenomegaly 
and diffuse lymphadenopathies. Historically, the genetic characterization of the disease has 
been hampered by the relatively low proliferative rate of WM cells, thus making karyotyping 
  challenging. The use of novel technologies such as fluorescence in situ hybridization, gene array, 
and whole genome sequencing has contributed greatly to establishing candidate genes in the 
pathophysiology of WM and to identifying potential treatment targets, such as L265P MYD88. 
The discovery of microRNAs and the recognition of epigenetics as a major modulatory mechanism 
of oncogene expression and/or oncosuppressor silencing have aided in further understanding the 
pathogenesis of WM. Once thought to closely resemble multiple myeloma, a cancer of terminally 
differentiated, immunoglobulin-secreting plasma cells, WM appears to genetically cluster with 
other indolent B-cell lymphomas such as chronic lymphocytic leukemia/small cell lymphoma. 
The relative high incidence of familial cases of WM and other B-cell malignancies has been 
helpful in identifying high-risk gene candidates. In this review, we focus on the established genes 
involved in the pathogenesis of WM, with special emphasis on the key role of derangement of 
the nuclear factor kappa B signaling pathway and epigenetic mechanisms.
Keywords: genetics, familial cases, NF-κB, whole genome sequencing, MYD88
Introduction
Waldenström’s macroglobulinemia (WM) is a non-Hodgkin’s lymphoma (NHL) 
typically characterized by bone marrow infiltration by lymphoplasmacytic cells 
and production of a serum monoclonal immunoglobulin (Ig) M.1 WM derives its 
name from Jan Gosta Waldenström, a Swedish physician and luminary who first 
reported on two patients presenting with oral mucosa bleeding, epistaxis, and diffuse 
lymphadenopathies.2 Laboratory evaluation of these patients revealed normochromic 
anemia, thrombocytopenia, elevated erythrocyte sedimentation rate, and decreased 
fibrinogen and albumin. Waldenström noticed two crucial differences between this 
condition and multiple myeloma (MM): first, his patients did not have any bone pain 
or bone lesions, and, second, the bone marrow was infiltrated by lymphocytic rather 
than plasmacytic cells.2,3 Waldenström’s preliminary observations have largely been 
included in the current diagnostic criteria for WM.
WM is defined by the presence of a monoclonal IgM (M spike) of any degree, more 
than 10% bone marrow involvement by a lymphoplasmacytic infiltrate, and presence 
of end organ damage directly attributable to either the B-cell clone or the M protein.3,4 
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The latter criterion distinguishes WM from smoldering WM, 
in which there is no end organ dysfunction directly attribut-
able to the cancer. IgM monoclonal gammopathy of unclear 
significance (MGUS), a benign condition with premalignant 
potential, has been recently reported to precede WM with a 
rate of progression of 2.0% to 2.5% per year. Three diagnostic 
criteria are required to be fulfilled for a diagnosis of IgM-
MGUS: ,10% lymphoplasmacytic infiltration of the bone 
marrow, ,3 g/dL IgM spike, and absence of symptoms or 
end organ damage attributable to WM.4
Ontologically, WM is thought to derive from post-
germinal-center B cells that have undergone the process 
of somatic hypermutation but not isotype class switching.5 
WM cells are characterized by a specific immunophenotype 
  (positive: surface IgM, cluster of differentiation (CD) 19, 
CD20, CD22, CD25, CD27, FMC7; negative: CD10, CD23, 
CD103, CD138; and variable CD5 expression), which is 
helpful in distinguishing WM from other NHL and MM that 
can appear morphologically similar.
WM is a rare cancer, affecting about six persons per 
million people, per year in the USA, with incidence increas-
ing with age. Median age at diagnosis is between 63 and 
68 years.6 Men are twice as commonly affected than women 
and incidence is 2–3 times higher in whites than in blacks.7
Patients with WM typically present with nonspecific 
symptoms such as asthenia and malaise, often related to 
anemia, which, together with a circulating monoclonal pro-
tein IgM detectable on serum protein electrophoresis and/or 
immunofixation, represents the most common laboratory 
abnormality.8 The etiology of the most common presenting 
symptoms and signs of WM can be explained by several 
mechanisms: cytopenias secondary to bone marrow infiltra-
tion by WM cells and impairment of normal hematopoiesis; 
hepatosplenomegaly and lymphadenopathy as a result of 
parenchymal infiltration by malignant cells; and peripheral 
neuropathy and hyperviscosity related to the nature and 
quantity of the M protein, respectively. Rarely, WM patients 
develop amyloid light-chain (AL) amyloidosis from deposi-
tion of monoclonal light chain, more often lambda.9 The latter 
diagnosis is associated with a dismal prognosis, especially 
when cardiac involvement is present.
Several negative prognostic factors have been identi-
fied in newly diagnosed WM patients and an internation-
ally recognized prognostic algorithm (the International 
Prognostic Scoring System [IPSS]) was recently developed 
to help risk-stratify WM patients.10 Age over 65 years, 
  hemoglobin , 11.5 g/dL, thrombocytopenia , 100,000/µL, 
β2-microglobulin . 3 mg/L, and monoclonal IgM . 7 g/dL 
are the adverse prognostic factors on which the IPSS is 
based.11
Although WM is incurable, it is typically character-
ized by an indolent clinical course. For this reason, active 
treatment is not recommended until symptoms arise and/
or end organ damage ensues. In particular, therapy should 
commence in the setting of hyperviscosity syndrome and 
AL amyloidosis. Although the median survival of WM 
patients has been estimated at around 5 years, this number 
is likely to overestimate the aggressiveness of the disease 
for two reasons.11 First, the estimation includes all causes 
of mortality rather than cancer-related mortality in a popu-
lation that is demographically at risk for other morbidities. 
  Second, this figure was obtained by calculating overall 
survival from the time of commencement of treatment, 
rather than diagnosis, not accounting thus for the months 
or years during which WM patients remain under close 
surveillance without therapy. Indeed, a recently published 
study found that disease-specific survival in patients with 
WM exceeds 10 years.10
The treatment armamentarium for WM currently includes 
the anti-CD20 monoclonal antibody rituximab, alkylating 
agents, purine nucleoside analogs, and the proteasome 
inhibitor bortezomib, either alone or in combination.12,13 
Bench and clinical research has focused on developing drugs 
against novel targets important to sustain the maladaptive 
interaction between the cancer clone and microenvironment, 
such as the mammalian target of rapamycin (mTOR) or 
phosphatidil insositol 3 kinase-protein kinase B (PI3K-AKT) 
pathway and the ubiquitin–proteasome axis.14,15 Autologous 
stem cell transplantation is used in selected patients, while 
allogeneic stem cell transplant is generally not implemented 
due to high procedure-related morbidity and mortality and 
the overall indolent course of the disease.16
Historically, cytogenetics has been difficult to perform in 
WM cells due to their low proliferation rate, hampering the 
possibility of obtaining metaphases. However, the introduc-
tion of fluorescence in situ hybridization (FISH), gene array, 
and whole genome sequencing has provided significant help 
in the pursuit of a genetic signature for WM that would help 
understand the pathogenesis of the disease and design target 
treatment.17
In this paper, we review the available data regarding 
target genes in WM, with a special emphasis on mutations 
in the nuclear factor kappa B (NF-κB) pathway, especially 
MYD88, and on recent findings in the field of microRNAs 
(miRs) and epigenetics. The most common genetic mutations 
in WM are summarized in Table 1.
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Table 1 Outline of the most frequently occurring genetic aberrancies in Waldenström macroglobulinemia (WM) with an emphasis on 
targeted genes
Chromosomal  
abnormality
Encoded  
protein
Incidence Function Comments
SNM 3p22.2 MYD88 90% Activator of canonical NF-κB •    Non-conservative, missense, gain of 
function, mutation in codon 265 (L265)
•    Identified via whole genome sequencing
+3 Unknown,  
possibly BCL6
10% Unknown •    Shared with MZL, CLL, and MM
+4 Unknown 10%–20% Unknown •    Familial studies suggest candidate gene to 
map on 4q33–4q34
•    Specific for WM
•    Occasionally the only genetic mutation
+6p Unknown 17% Unknown •    Occurs concomitantly with -6q
6q-
Locus 21
Locus 23
Blimp1
TNFAIP3
40%–50%
Transcription repressor
Ubiquitin-editing enzyme
•    Del6q discriminates WM from IgM-MGUS
•    Occurs commonly in MM and NHL
7q- Unknown 7% •    Shared with MZL, CLL, and MM
11q- Possibly ATM 10% Serine-threonine kinase.  
Activates P53, leading to DNA repair,  
cell cycle arrest, and apoptosis
•    Shared with MZL, CLL, and MM
13q14- miR 15A  
and 16-1
10%–13% Target proteins involved in cell cycle,  
proliferation and anti-apoptosis
•    Shared with MZL, CLL, and MM
14q32- TRAF3 5% Inhibitor of noncanonical NF-κB
17p13- P53 8% DNA repairer, cell cycle arrester,  
and apoptosis generator
•    Associated with shortened DFS but  
not OS
+18 BCL2, Malt1 15% Anti-apoptotic, NF-κB activator •    Shared with MZL, CLL, and MM
•    Often associated with +4
Abbreviations: ATM, ataxia telangiectasia mutated; CLL, chronic lymphocytic leukemia; DFS, disease-free survival; Ig, immunoglobulin; MGUS, monoclonal gammopathy of 
unknown significance; MM, multiple myeloma; MZL, marginal zone lymphoma; NHL, non-Hodgkin’s lymphoma; OS, overall survival; SNM, single-nucleotide mutation.
Familial WM cases: an insight into 
high-risk gene candidates
Although the majority of WM cases are sporadic, familial 
clustering of WM or co-aggregation with other hematologic 
malignancies, particularly chronic lymphocytic leukemia 
(CLL), Hodgkin’s lymphoma and NHL, has been reported 
in as many as 20% of cases.18,19 Common genetic variants 
in 152 genes involved in cell proliferation, apoptosis, 
inflammation, and DNA repair were investigated in families 
with two or more individuals affected by the same type 
of lymphoma, resulting in over 1500 genotyped single-
nucleotide pairs (SNPs).20 SNPs in the genes codifying for 
B-cell lymphoma 2 (BCL2), interleukin 10 (IL10), tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL), 
and tumor necrosis factor-related apoptosis-inducing ligand 
receptor 1 (TRAILR1) were associated with both WM and 
CLL; SNPs in IL-6 were common between WM and Hodg-
kin’s lymphoma, thus providing a potential explanation for 
their shared familial clustering.
Family studies also revealed that first-degree relatives 
of WM patients carry an increased incidence of the prema-
lignant condition IgM-MGUS.21,22 Linkage studies in such 
families identified chromosome 1q, 3q, and 4q as potentially 
responsible for this genetic predisposition. Paratarg-7 (P-7), 
a ubiquitous protein whose function is unclear, was reported 
to be the antigenic target of circa 15% monoclonal IgA 
and IgG in patients with MGUS or MM.23,24 Similarly, a 
  German group showed the monoclonal protein of patients 
with WM or IgM-MGUS reacts against a hyperphosphory-
lated form of P-7 (pP-7) in around 11% of cases.25 Family 
linkage   analysis showed pP-7 to be inherited according to 
an autosomal dominant pattern.26 Given the low prevalence 
of pP-7   expression in the healthy population (2%), indi-
viduals expressing hyperphosphorylated P-7 proved six 
times more likely to develop WM or IgM-MGUS than the 
general population, thus suggesting a causative role for this 
antigenic target.25
Similarities and differences between 
WM and other hematologic 
malignancies: from karyotype  
to gene-expression profiling (GEP)
WM shares with several B-cell derived malignancies 
(marginal zone lymphoma (MZL), CLL, and MM) several 
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genetic aberrancies such as trisomy 3, trisomy 18, deletion 
7q, deletion 11q, and deletion 13q.27 In contrast to MM and 
MZL, WM cells only rarely carry a translocation involving 
the heavy immunoglobulin (IgH) locus (3%).28 Trisomy 4 is 
identified in about 10%–20% of WM patients and appears 
to be specific for WM and occasionally the only genetic 
aberration noticed.29 Although no discrete candidate gene 
has yet been identified on chromosome 4, a genome-wide 
linkage analysis in individuals from a family with high 
prevalence of WM showed high nonparametric linkage on 
4q33–4q34, suggesting a pathogenic role for the gene(s) 
contained in this region.30 Trisomy 18, a frequently found 
abnormality in MZL, associates with trisomy 4 and is 
present in about 15% of WM patients.31 Deletion 17p is 
typically associated with loss of TP53 and underscores a 
poor prognosis in CLL, MM, and MZL. Del17p occurs in 
about 8% of WM patients and correlates with shortened 
disease-free survival but not overall survival, thus sug-
gesting no clear role for it as a negative prognostic factor 
in WM.31
Contradicting what was previously predicated, GEP 
in B-cell-derived malignancies showed WM to cluster 
more closely to CLL than MM.32,33 Using a class predic-
tion model, four genes were able to discriminate between 
CLL- and WM-derived cells with 100% accuracy: lymphoid 
enhancer-binding factor 1 (LEF1), ataxin 1 (ATXN1), 
fibromodulin (FMOD), and myristoylated alanine-rich 
protein kinase C substrate (MARCKS). The first three were 
upregulated in CLL while MARCKS was upregulated in 
WM. GEP also revealed a higher expression of IL-6 in 
WM than in both MM and CLL. While the role of IL-6 in 
mediating cell proliferation and drug resistance in MM 
has been established, its function in the pathogenesis of 
WM remains unclear.34–37 It is widely accepted that IL-6 
activates the mitogen-activated protein kinase/  extracellular 
signal-regulated kinase (MAPK/ERK) pathway and the 
transcription factor signal transducer and activator of 
transcription (STAT) 3 via the tyrosine kinase receptor 
signaling of Janus kinase 1 and 2. In the absence of any 
identified activating mutation of the MAPK/ERK pathway 
in WM, IL-6 is believed to be directly responsible for the 
chronic activation of this signaling cascade.38 Moreover, the 
activation of the Janus kinase/STAT pathway by cytokines 
such as IL-6 and IL-21 has been recently advocated as 
the mechanism underlying the hypersecretion of IgM by 
WM cells, which is a major contributor to WM-related 
morbidity.39,40
Deletion of the long arm  
of chromosome 6: the most 
common and first identified 
karyotype abnormality in WM
The indolent nature of WM is reflected in the low prolif-
eration rate of WM cells, which has historically compro-
mised the success of karyotype analysis with conventional 
  cytogenetics.41 The in vitro use of immunostimulatory fac-
tors and cytokines has been instrumental in increasing the 
mitotic rate of WM cells and thus the success rate of con-
ventional cytogenetics, which is currently exceeding 80% in 
several series.31 In a recently published randomized clinical 
trial conducted in 174 newly diagnosed WM patients, an 
abnormal karyotype was identified by conventional cytoge-
netics in 47% of patients, with translocations being present 
in about 35% of cases.31
Deletion 6q (-6q or del6q) is the first and most frequently 
identified chromosomal abnormality in WM.42 Recent studies 
based on high-resolution array-based comparative genom-
ics hybridization and FISH reported the presence of del6q 
in about 40%–50% of WM patients.27,43 Importantly, the 
presence of this mutation proved to confer an unfavorable 
prognosis in active WM.41,44 While frequent in WM, del6q 
is not exclusive to this disease. Loss of four distinct mini-
mal deleted regions on the long arm of chromosome 6 was 
detected in several B-cell-derived malignancies, including 
MM and MZL.45
More sophisticated techniques such as array-based 
comparative genomics hybridization have identified B 
lymphocyte-induced maturation protein 1 (BLIMP1) and 
tumor necrosis factor α-induced protein 3 (TNFAIP3 or 
A20) as candidate tumor suppressor genes mapping in 
two distinct minimal deleted regions on the long arm of 
chromosome 6.32,46 The function of BLIMP1 and TNFAIP3 
is discussed following.
BLIMP1: an oncosuppressor crucial  
for plasma cell differentiation
BLIMP1, also known as positive-regulatory domain I binding 
factor 1 or PR domain containing 1 (PRDM1), a transcription 
factor with mainly repressor function, plays a pivotal role 
in orchestrating the differentiation of B cells into plasma 
cells.47–49 It exerts gene repression both directly, via a histone 
methyltransferase domain (PR domain), and indirectly, via five 
zinc-finger domains that bind to the DNA and recruit histone 
deacetylases (HDACs) of the Groucho family.50,51 In humans, 
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BLIMP1 exists in two different isoforms arising from alter-
nate promoters: PRDM1α encodes the full-length BLIMP1 
protein, while PRDM1β lacks the first 101 amino acids, result-
ing in loss of most of the PR domain and reduced function 
as a transcriptional repressor.52 BLIMP1 orchestrates mature 
plasma cell differentiation by suppressing genes necessary for 
commitment and maintenance of B-cell identity and for cell 
proliferation.53 Among the genes silenced by BLIMP1 are the 
B-cell surface markers CD19, CD20 and CD45; MIP-1β and 
CD69, which participate in B-cell activation; the transcrip-
tion factors BCL6, PAX5, STAT6, and several B-cell-receptor 
signaling cascade molecules such as SYK, BLNK, CD79a, 
PKCβ, and LYN.54,55 PAX5 is fundamental for commitment to 
B-cell lineage during early hematopoiesis and its suppression 
is necessary for B cells to differentiate into plasma cells.56–58 
Among its functions, PAX5 represses the transcription factor 
X-binding protein-1 (XBP-1), the only known substrate of 
the endoribonuclease activity of inositol-requiring enzyme 
(IRE-1), one of the three sensor branches in mammalian 
unfolded protein response (UPR).59,60 XBP-1 was shown to be 
necessary for terminal differentiation of B lymphocytes into 
plasma cells by inducing expression of genes involved in the 
process of immunoglobulin synthesis and folding.49,61
Class II transactivator (CTIIA), the master regulator of 
expression of major histocompatibility complex class II, 
is also a target of BLIMP1-mediated gene repression, thus 
accounting for the downregulation of major histocompat-
ibility complex class II in antibody-secreting plasma cells.62 
BLIMP1 also mediates the repression of genes involved in 
DNA replication and repair and in cell cycle progression, 
including C-MYC, which is necessary, but does not suffice 
to drive the terminal differentiation of B lymphocytes.63 In 
light of the spectrum of genes inhibited by BLIMP1, a role as 
a tumor suppressor gene has been recently proposed.64
TNFAIP3: a key molecule  
in terminating canonical NF-κB 
pathway activation
Initially identified as a gene induced by TNF-α, TNFAIP3 
(also known as A20) codifies for a downstream molecule 
in the NF-κB pathway and exerts a crucial function in the 
negative feedback loop that terminates NF-κB signaling.65 
Its induction is mediated by engagement of several recep-
tors involved in inflammation and infection signaling, most 
prominently tumor necrosis factor receptor 1 (TNFR1), the 
B-cell receptor CD40, toll-like receptors (TLRs), NOD-like 
receptors, and the interleukin-1 receptor (IL-1R).66
Structurally, TNFAIP3 is an ubiquitin-editing enzyme 
characterized by an N-terminal deubiquitin (DUB) domain 
and a C terminus containing seven zinc-finger domains with 
direct ubiquitin binding and ubiquitin ligase (E3) activity.67 
Among the substrates of the DUB activity of TNFAIP3 is 
receptor-interacting protein 1 (RIP1). In response to TNF 
alpha signaling, RIP1 is ubiquitinated at lysine (K) 63, 
which results in recruitment of transforming growth fac-
tor β-activated kinase 1 (TAK1), TAK1-binding protein 2, 
and IκB kinase γ, also known as NEMO. This complex is 
responsible for the phosphorylation of NF-κB inhibitor-α, 
IκBα which results in its polyubiquitination via K48 and 
subsequent proteasomal degradation. Proteasome-mediated 
degradation of IκBα causes activation of the canonical 
NF-κB pathway. TNFAIP3 causes inhibition of the canonical 
NF-κB pathway by deubiquitinating RIP1, thus abolishing 
the recruitment of the TAK1, TAK1-binding protein 2, and 
NEMO complex.
The E3 ubiquitin ligase, TNF receptor-associated factor 
6 (TRAF6) is also substrate of the DUB activity of A20.68 
Upon engagement of TLR4 and IL-1R, TRAF6 binds to 
Ubc13 (or Ubc5), an E2, ubiquitin-  conjugating enzyme. 
This association causes TRAF6 activation via K63 autou-
biquitination. Polyubiquitinated TRAF6 activates the IκB 
kinase complex (IKK), resulting in IκB phosphorylation, 
its proteasomal degradation, and activation of the canonical 
NF-κB pathway.69
The E3 domain of A20 is involved in K48-
  polyubiquitination of several E2 enzymes, including UBCH5 
and UBC13, which promotes the activation of the signaling 
molecules RIP1, TRAF6, IκB kinase γ, and RIP2 via K63 
ubiquitination. In a close regulatory feedback, RIP1 is also 
a direct target of the ubiquitin ligase activity of TNFAIP3, 
leading to its proteasomal degradation.66
TNFAIP3 appears to mediate inhibition of the NF-κB 
pathway also via direct binding of ubiquitin chains on 
IKK and TNFR1, resulting in non-catalytic interference 
with their signaling function. In vitro studies have shown 
that the zinc-finger domains 4 and 7 are responsible for 
this action.70
Given the activity of A20 in terminating NF-κB signaling, 
its loss of function by mutation or deletion has been advocated 
to play a major role in several inflammatory, autoimmune, and 
malignant human diseases, including WM.65,66 In particular, 
TNFAIP3 is deleted in around 40% of WM patients, with 5% 
presenting with bi-allelic inactivation, suggesting that it has 
an important role as oncosuppressor in this disease.46
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Importance of non canonical NF-κB 
pathway deregulation in the 
pathogenesis of WM: identification 
of mutations in tumor necrosis 
factor-receptor-associated  
factor 3 (TRAF3)
The canonical pathway of NF-κB activation involves phos-
phorylation of IκB by the IKK complex (composed by two 
catalytic subunits, IKKα and IKKβ, and a regulatory sub-
unit, IKKλ), resulting in its degradation via the   proteasome. 
  Proteolysis of the inhibitory subunit relieves cytosolic 
sequestration of the active dimers 50/RelA and p50/c-Rel, 
which then translocate to the nucleus and exert their function 
as transcription factors. Instead, the noncanonical pathway of 
NF-κB activation requires proteasome-mediated proteolytic 
activation of the precursor protein of NF-κB2 (p100) into 
the p52 active component in order to allow its dimerization 
with RelB and thus activation of signaling.71 Such activat-
ing cleavage occurs after IKKα-mediated phosphorylation 
and ubiquitination of p100, a signaling induced by NF-κB-
inducing kinase (NIK). TRAF3 mediates proteasomal deg-
radation of de novo synthesized NIK by recruiting the E3, 
ubiquitin ligase complex, TRAF2-cIAP (cellular inhibitor 
of apoptosis). In the absence of TRAF3, NIK is not targeted 
for degradation, thus resulting in chronic NF-κB signaling. 
This function has been advocated to explain the tumor sup-
pressor role of TRAF3.72 This gene is located on the long arm 
of chromosome 14 at cytoband 32.32. Bi-allelic deletions or 
inactivating mutations at this site were noticed in about 5% 
of WM patients in a recently published microarray-based 
study of 42 WM patients.46,73
Impact of whole genome sequencing: 
the identification of MYD88
Cytogenetics, FISH, and GEP provided significant infor-
mation regarding the genetics of WM but did not reveal 
any specific molecular signature capable of distinguishing 
WM from other B-cell malignancies.27 This observation 
suggests that SNPs, small genetic mutations, and/or epi-
genetic mechanisms might be responsible for the unique 
WM phenotype. Whole genome sequencing and Sanger 
sequencing revealed the presence of a recurrent, missense, 
single-nucleotide mutation on chromosome 3p22 in 30 
patients with WM.74
This non-synonymous mutation causes a leucine to 
proline substitution in codon 265 (L265P) of the Myeloid 
Differentiation Primary Response Gene 88 (MYD88).74 
MYD88 is believed to be a key player in the activation of 
the canonical NF-κB pathway, downstream of TLR and 
IL-1R signaling.75,76 Upon TLR or IL-1R activation, MYD88 
homodimerizes and forms a complex with interleukin-1 
receptor-associated kinase (IRAK) 4, resulting in activa-
tion of IRAK1 and IRAK2.77 The former is responsible for 
the activation of TRAF6, which cooperates with TAK1 in 
phosphorylating and activating the IKK complex.77,78 The 
latter targets IκB for degradation, thus leading to canonical 
NF-κB signaling.
The L265P MYD88 mutation was first reported in 
diffuse large B-cell lymphoma and has recently been 
shown to be present in over 90% of WM patients when 
assessed via whole genome sequencing, Sanger sequenc-
ing, or allele-specific polymerase chain reaction (AS-
PCR).74,79,80 Given the role of MYD88 as an amplificator 
and transducer molecule downstream of TLR and IL-1R, 
the L265P mutation is believed to result in gain of 
function and chronic activation of the canonical NF-κB 
pathway.
While L265P MYD88 was detected in only 10%–12% 
of IgM-MGUS via whole genome sequencing, in a recent 
study that utilized AS-PCR, it was found present in around 
50% of 24 patients analyzed. This observation suggests that 
L265P MYD88 mutation might be an early oncogenic or 
driving mutation in the evolution of IgM-MGUS to WM.80 
Interestingly, the three IgM-MGUS patients who progressed 
to WM in the same study presented a high level of expression 
of L265P MYD88 mutation when assessed by real-time poly-
merase chain reaction and were also all positive for mutation 
on sequencing. These data suggest a potential prognostic role 
of L265P MYD88 in stratifying IgM-MGUS patients for risk 
of progression to WM.
In WM patients, the presence of L265P MYD88 correlated 
with a higher burden of bone marrow involvement compared 
with patients who did not carry the mutation and response to 
treatment resulted in decreased levels of L265P MYD88 as 
assessed by real-time AS-PCR.80 Moreover, when combined 
with immunoglobulin heavy chain variable region (IGHV) 
mutation status, the L265P MYD88 mutation appears to out-
line a unique genetic signature that distinguishes WM from 
other similar B-cell malignancies.81 Taken together, these 
data suggest that L265P MYD88 may be used as a molecular 
marker for diagnosis, risk stratification, and monitoring of 
disease response to treatment in patients with WM. Given its 
putative role in the uncontrolled activation of the canonical 
NF-κB pathway, L265P MYD88 is an extremely attractive 
target for pharmacologic inhibition in WM.
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Epigenetics and miRs: a different way 
of targeting genes in malignancy
“Epigenetics” (from the ancient Greek “epi,” meaning above, 
and “genesis,” meaning origin) is the study of heritable 
changes in gene expression caused by mechanisms other than 
modifications in the nucleotide sequence. DNA methylation, 
acetylation, and miRs are some of the major mechanisms to 
modulate gene expression and cellular phenotype without 
altering gene sequence.
miRs are noncoding RNA oligonucleotides about 20 
bases long that exert their function by binding to newly 
transcribed, target messenger RNAs, thus inhibiting their 
translation. Each miR can interfere with the translation of a 
pool of genes, rather than a single transcript, thus allowing 
modulation of multiple targets at once. Recently, miRs have 
been reported to play a major role as either oncogenes or 
oncosuppressors in both hematologic and solid malignancies, 
depending on the function of their target genes.82
Via comparative analysis of miR expression in WM cells 
and their normal counterparts (CD19+ cells isolated from 
the peripheral blood and bone marrow of healthy donors), 
a distinct pattern has emerged that distinguishes the former 
from the latter. WM cells showed upregulation of miRs 
155, 184, 206, 363, 494, and 542-3p and downregulation of 
miR-9.83 In patients, this signature miR profile correlated 
with an elevated IPSS score at diagnosis, thus suggesting a 
role for it as a prognostic factor. Moreover, in vitro treatment 
with anti-WM drugs such as rituximab, perifosine, and bort-
ezomib resulted in decreased level of the upregulated miRs 
and increased miR-9 level, suggesting miRs have a primary 
etiopathologic role and potential function as a predictive 
factor of response to therapy.
miR-155 was shown to be overexpressed in several can-
cers of B-cell origin and to act as an oncogene by deregulating 
NF-κB, PI3K-AKT and MAPK/ERK signaling pathways.84–87 
miR-155 was also shown to be involved in WM cell adhesion 
to fibronectin and in chemotaxis in response to stromal-
derived factor 1 (SDF-1), thus suggesting a key role in 
mediating the localization and retention of cancer cells into 
the nurturing bone marrow niche. To further substantiate this 
function, miR-155 knockdown WM cells were investigated 
and showed impaired homing and trafficking when injected 
into mice.88 Further, these animals were noticed to have 
prolonged survival when compared with animals injected 
with wild-type cells. GEP also showed decreased expression 
of cyclins D1, D2, D3, and E; of cyclin-dependent kinase-2, 
-4, and -6; and increased expression of the cyclin-dependent 
kinase inhibitors p18, p19, p21, and p27 which altogether 
resulted in G1-G0 arrest and decreased progression to S 
phase. miR-155 knockdown in WM cells also results in 
decreased Mdm2 expression with consequent increased p53 
level and activity.89
miR-206 and miR-9 have an amplified epigenetic 
function by targeting histone deacetylase (HDAC) and 
histone acetyltransferase (HAT), respectively. In particular, 
overexpression of miR-206 in WM results in increased levels 
of HDAC-2, -4, -5, -6, -8 and -9 while the downregulation 
of miR-9 mediates decreased expression of HAT1, 2 and 3. 
Overall, the net balance of their functions is increased his-
tone acetylation leading to enhanced gene transcription.90
Deletion of 13q14 was reported in about 10%–13% of 
patients with WM.27,31 The minimal deleted region of this 
genetic abnormality includes the miR genes MIRN15A 
and MIRN16-1, which have been previously reported to 
be downregulated or lost in about 70% of CLL patients.91 
Both miRs are believed to act as tumor suppressors by 
inhibiting the transcription of a pool of mRNAs encoding 
for proteins involved in cell cycle, proliferation, and anti-
apoptosis, such as BCL2.92 Previously regarded as a sign 
of disease progression and aggressive biologic behavior, 
deletion 13q was recently reported to have no prognostic 
value in WM.31
Conclusion
Genetic studies in WM have been historically hampered by 
the low proliferation rate of tumor cells. With the evolu-
tion of methods and technologies in the biomedical field, 
the past 15 years have witnessed an exponential growth in 
knowledge about gene aberrations in WM. This increased 
fund of information is helping to delineate a genomic sig-
nature that will serve not only as a risk stratifying measure 
for WM patients but also as a tool to better understand the 
etiopathogenic bases of the disease.
From standard cytogenetics to gene array and whole 
genome sequencing, aberrations in the NF-κB pathway have 
been proven to play a central role as a pathogenic mechanism 
in WM, opening the way toward the design of target   therapies. 
WM cells have also been shown to harbor mutations in genes 
coding for miRs, HATs, and HDACs, with a net result of 
generalized increase in gene   transcription. These data have 
helped expand our understanding of the role of epigenetics in 
tumorigenesis and paved the way for the design of therapies 
to target miRs as a tool to affect multiple potential targets 
simultaneously.
On the basis of the recently gathered genetic data, in 
particular the highly represented L265P MYD88 mutation, 
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the scientific community looks forward to the identification 
of the molecular mechanisms of WM pathogenesis and the 
development of specific inhibitors against this newly identi-
fied molecular target.
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